

Gastroenterology

Volume 164 / Issue 2

February 2023

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER



Unfermented β -fructan Fibers Fuel Inflammation in Select Inflammatory Bowel Disease Patients. See article by Armstrong, et al, page 228 for additional information.

IN MEMORIAM

- 169 **In Memoriam: Robert K. Ockner, MD**
N. M. Bass

DIVERSITY, EQUITY, AND INCLUSION IN GI

- 171 **Promoting Prognostic Understanding and Health Equity for Patients With Advanced Liver Disease: Using "Best Case/Worst Case"**
Nneka N. Ufere, A. El-Jawahri, C. Ritchie, J. C. Lai, and M. L. Schwarze

MENTORING, EDUCATION, AND TRAINING CORNER

- 177 **"Am I Going to Die?": Delivering Serious News to Patients With Liver Disease**
A. A. Patel, R. M. Arnold, T. H. Taddei, and C. D. Woodrell

EDITORIALS

- 182 **Promote or Prevent? Gut Microbial Function and Immune Status May Determine the Effect of Fiber in Inflammatory Bowel Disease**
A. Shin and P. C. Kashyap
See Armstrong HK et al on page 228.

- 184 **Shining a Light on Barrier Function**
M. Friedrich and S. Travis
See Rath T et al on page 241.

GASTRO CURBSIDE CONSULT

- 187 **An Unexpected Esophageal Lesion in a Patient With Muir-Torre Syndrome**
N. Ellenberger, W. Tränkenschuh, and M. Casper

Video Related article in CGH Hot Papers From New Investigators

CME quiz Editorial accompanies this article Additional online content available Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2023 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

191 A Rare Cause of Peri-esophageal Cystic Lesion*X. Dong and D. Wu***194 An Unusual Duodenal Finding***K. Estes, D. Dhall, and F. Weber***196 An Unusual Cause of Obstructive Jaundice***P. Liu, X.-Z. Tan, and R. Wan***ELECTRONIC GASTRO CURBSIDE CONSULT**

For a full list, please see the table of contents online at www.gastrojournal.org.

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY**198 Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy***D. Chrysostomou, L. A. Roberts, J. R. Marchesi, and J. M. Kinross***ORIGINAL RESEARCH****Full Reports****GI Cancer****214 Loss of SUV420H2-Dependent Chromatin Compaction Drives Right-Sided Colon Cancer Progression***V. Boonsanay, M. H. Mosa, M. Looso, D. Weichenhan, F. Ceteci, L. Pudenko, A. Lechel, C. S. Michel, C. Künne, H. F. Farin, C. Plass, and F. R. Greten*

Right-sided colorectal cancer is characterized by distinct epigenetic marks that can be exploited therapeutically, thus creating a specific therapeutic window for these tumors.

Inflammatory Bowel Disease**228 Unfermented β -fructan Fibers Fuel Inflammation in Select Inflammatory Bowel Disease Patients***H. K. Armstrong, M. Bording-Jorgensen, D. M. Santer, Z. Zhang, R. Valcheva, A. M. Rieger, J. Sung-Ho Kim, S. I. Dijk, R. Mahmood, O. Ogungbola, J. Jovel, F. Moreau, H. Gorman, R. Dickner, J. Jerasi, I. K. Mander, D. Lafleur, C. Cheng, A. Petrova, T.-L. Jeanson, A. Mason, C. M. Sergi, A. Levine, K. Chadee, D. Armstrong, S. Rauscher, C. N. Bernstein, M. W. Carroll, H. Q. Huynh, J. Walter, K. L. Madsen, L. A. Dieleman, and E. Wine*

See editorial on page 182.

Dietary β -fructan fibers, if not effectively fermented by gut microbes, induce an inflammatory response and gut barrier changes in patients with inflammatory bowel disease via TLR2 and activation of NLRP3.

241 Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERICA Trial*T. Rath, R. Atreya, J. Bodenschatz, W. Uter, C. E. Geppert, F. Vitali, S. Fischer, M. J. Waldner, J.-F. Colombel, A. Hartmann, and M. F. Neurath*

See editorial on page 184.

Healing of the intestinal barrier is associated with decreased risk of disease progression of inflammatory bowel diseases, with superior prediction of the further course of disease by barrier healing compared to endoscopic and histologic remission.

Intestinal Inflammation

- 256** **G9a Modulates Lipid Metabolism in CD4 T Cells to Regulate Intestinal Inflammation**
 G. P. Ramos, A. O. Bamidele, E. E. Klatt, M. R. Sagstetter, A. T. Kurdi, F. H. Hamdan, R. L. Kosinsky, J. M. Gaballa, A. Nair, Z. Sun, S. Dasari, I. R. Lanza, C. N. Rozeveld, M. B. Schott, G. Urrutia, M. S. Westphal, B. D. Clarkson, C. L. Howe, E. V. Marietta, D. H. Luckey, J. A. Murray, M. Gonzalez, M. B. Braga Neto, H. R. Gibbons, T. C. Smyrk, S. Johnsen, G. Lomberg, and W. A. Faubion

Epigenetic control of cholesterol metabolism in CD4 T cells can be explored as therapy for intestinal inflammation through the generation of regulatory immune cells in vivo.

Gut Microbiota

- 272** **Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications**
 N. Nagata, T. Takeuchi, H. Masuoka, R. Aoki, M. Ishikane, N. Iwamoto, M. Sugiyama, W. Suda, Y. Nakanishi, J. Terada-Hirashima, M. Kimura, T. Nishijima, H. Inooka, T. Miyoshi-Akiyama, Y. Kojima, C. Shimokawa, H. Hisaeda, F. Zhang, Y. K. Yeoh, S. C. Ng, N. Uemura, T. Itoi, M. Mizokami, T. Kawai, H. Sugiyama, N. Ohmagari, and H. Ohno

We characterize interrelationships between gut microbes, metabolites, and cytokines in COVID-19 and its complications and validate the results with follow-up, other disease, and non-Japanese data sets.

RESEARCH LETTERS

- 289** **Pancreatitis-Associated PRSS1-PRSS2 Haplotype Alters T-Cell Receptor Beta (TRB) Repertoire More Strongly Than PRSS1 Expression**
 D. Fu, B. M. Blobner, P. J. Greer, R. Lafyatis, M. D. Bellin, and D. C. Whitcomb, for the Prospective Autos Study, The GREAT1 Study, and the North American Pancreatitis Study Group
- 293** **Endoscopist Characteristics and Polyp Detection in Colonoscopy: Cross-Sectional Analyses of Screening of Swedish Colons**
 M. Sekiguchi, M. Westerberg, A. Ekblom, R. Hultcrantz, and A. Forsberg
- 296** **Final Analysis of Diagnostic Endoscopic Resection Followed by Selective Chemoradiotherapy for Stage I Esophageal Cancer: JCOG0508**
 K. Nihei, K. Minashi, T. Yano, T. Shimoda, H. Fukuda, and M. Muto, on behalf of the JCOG-GIESG Investigators
- 300** **Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine**
 Z. Liu, J. L. Alexander, K. W. Lin, VIP Study Investigators, T. Ahmad, K. M. Pollock, and N. Powell

GASTRO DIGEST

- 304** **Eliminating Pathobionts With Bacteriophages: A Novel Approach to Reduce Gut Inflammation in Inflammatory Bowel Diseases?**
 E. Wine
- 304** **A deCIDEly New Germline Mutation That Protects Against Liver Disease**
 B. J. DeBosch
- 305** **An Epidemic of Acute Hepatitis of Unknown Etiology in Children**
 S. Lens

CORRESPONDENCE

- 307** **Is a Protective Stoma Mandatory in Anti-Tumor Necrosis Factor-Treated Crohn's Disease Patients Undergoing Surgery?**
 A. Resegotti and D. G. Ribaldone

- 307 Controversy of Preoperative Exposure to Tumor Necrosis Factor Inhibitors in Surgical and Infectious Complications of Inflammatory Bowel Disease**
Z. Zhu, Z. Gao, and K. Li
- 308 Reply**
B. L. Cohen, P. Fleshner, and B. E. Sands
- 310 Clustering of Esophageal Cancer: Differences by Histology**
J. H. Rubenstein
- 310 Bile and Liver in Pregnancy: No One Split Apart What God Has Joined Together**
A. Maringhini
- 311 Reply**
C. Williamson and N. Terrault
- 313 Corrections**

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

**Sample
mailing
label**

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

Your Account Number

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001